GLYKOGEN LIMITED
Verified IntelGlykoGen aims to develop a pipeline of anti-glycan antibodies to target specific, currently ‘hard to treat’ cancers, including pancreatic cancer, using an innovative and patentable process. GlykoGen’s vision is the delivery of more effective, less-invasive/destructive therapies for cancer, targeting cancer cells through their surface glycans. Glycans are of interest in the study of cancer because they play a role in almost every biological process and are involved in every major disease. However, their role in cancer is not yet well explored, due to the difficulties of producing antibodies to glycans.
GlykoGen aims to develop a pipeline of anti-glycan antibodies to target specific, currently ‘hard to treat’ cancers, including pancreatic cancer, using an innovative and patentable process. GlykoGen’s vision is the delivery of more effective, less-invasive/destructive therapies for cancer, targeting cancer cells through their surface glycans. Glycans are of interest in the study of cancer because they play a role in almost every biological process and are involved in every major disease. However, their role in cancer is not yet well explored, due to the difficulties of producing antibodies to glycans.
Corporate Firmographics
Entity classification and operating profile
- Industry
- General
- Company Type
- Privately Held
- Founded
- Undisclosed
- Employee Bracket
- 1-10
- Estimated Revenue Range
- Undisclosed
Geographic Coordinates
Headquarters address and regional territory
- Street Address
- Countesswells Road Scotland Aberdeen
- City
- —
- Region / State
- City of Aberdeen
- Postal Code
- AB15 8QH
- Country
- United Kingdom
Digital Presence & Footprint
Verified domains, socials, and directory profiles
Frequently Asked Questions
Verified business inquiries and firmographic telemetry for GLYKOGEN LIMITED.